Metagen Therapeutics, Inc.
Building a stable supply chain to promote Fecal Microbiota Transplantation (FMT) and developing FMT formulations
FMT is currently used in advanced medical treatment for pseudomembranous enteritis and clinical research for inflammatory bowel disease. However, issues remain to be addressed, such as designing quality standards for FMT formulations and building a supply chain. Therefore, we will build a stable supply chain for safe FMT formulations that conform to global standards and promote the spread of FMT in Japan. In addition, we will expand our business field to microbiome drug discovery by utilizing intestinal microbiota data.
- Establishment Date
- January 2020
- Business
- Medical treatment and drug discovery business utilizing microbiome science, etc.
- CEO
- Taku Nakahara, President and CEO
KII’s Perspective
Metagen Therapeutics is composed of a team with one of the leading track records in intestinal microbiota research in Japan, with hopes of creating not only FMT formulations but also new microbiome drug discovery pipelines and delivering treatment options to patients with various diseases.
KII growth support
Business alliance support, Sales strategy planning support, Public relations support, Administrative structure enhancement support, Dispatch of board observers
